comprehensive -WSS

comprehensive

author：focus 2025-10-03 00:07:47 - browse：35

Illustration fo a pink arrow pointing downward. -- biotech coverage from STAT — Adobe

SAN DIEGO — Ventyx Biosciences reported on Monday that it was ending development of an experimental drug for treating plaque psoriasis though it proved safe and moderately effective in a mid-stage trial. Within hours, the company’s stock tanked by more than 80%.

That’s because the company announced that the small molecule, VTX958, had not met the biotech’s internal goals to advance to the next phase of clinical development. Ventyx said it would end work on the drug, which targets the signaling molecule TYK2, as a treatment for psoriasis and psoriatic arthritis.

Shares in Ventyx plummeted from $14.09 at market close to as little as $2.72 during after-hours trading. In the process, the company’s market value dropped from $830 million to around $160 million. Ventyx is now trading below its cash balance, which was $300 million as of the end of September.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Virginia high school admissions case could be legal follow
Next article： Stop the failed accountable care organization experiment

knowledge

WSS

How to address the problem of discarded donor organs

SCOTUS questions limit to govt efforts to fight misinformation

Creating egg and sperm cells from stem cells raises ethical issues

RSV vaccines may be linked to small increased risk of developing GBS

Congress gives doctors Medicare pay bump

Readout LOUD Podcast: Legal insider trading, booming biotech stocks

hotspot

comprehensive

hotspot

Indiana Supreme Court upholds abortion ban, says state constitution gives only limited protections

Kenai launches with $82 million for Parkinson’s stem cell therapy

Hepatitis C has a cure — but many Americans still lack access to it

Change Healthcare cyberattack outage could last weeks

FDA approval of Sarepta Duchenne genetic therapy gives me hope

Gene editing the human germline: What are the risks?

The cancer drug shortage isn’t new — and neither are the solutions

RSV vaccines may be linked to small increased risk of developing GBS

New air purifier tech could be key to improving indoor air quality

Covid isolation guidance eased by the CDC

entertainment

Covid isolation guidance eased by the CDC

Plastic surgeons increase patient psychiatric screenings

Intermittent fasting comes with a heart risk? Not so fast

Creating egg and sperm cells from stem cells raises ethical issues

Abortion pill mifepristone to soon be dispensed at CVS, Walgreens

Readout LOUD Podcast: Legal insider trading, booming biotech stocks

hotspot

knowledge

hotspot

knowledge